UK's NICE in first HTA (health technology assessment) judicial review
This article was originally published in Clinica
Executive Summary
The UK's National Institute for Health and Clinical Excellence (NICE) is this week facing its first judicial review over its limited approval of therapies for Alzheimer's disease. In a move that could have implications for the wider appraisal work conducted by the health technology assessment (HTA) body, NICE is being urged to reveal the complex mathematical model it uses to determine clinical and cost-effectiveness.